CA
LAB icon

Clearstead Advisors’s Standard BioTools LAB Stock Holding History

Clearstead Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10 Buy
+11
New +$10 ﹤0.01% 3621
2025
Q4 		– Sell
-215
Closed -$280 – 3029
2025
Q3 		$280 Buy
215
+2
+0.9% +$3 ﹤0.01% 2816
2025
Q2 		$256 Buy
+213
New +$236 ﹤0.01% 2554

Other funds holding LAB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Clearstead Advisors's LAB Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Standard BioTools (LAB) in Q2 2026: 11 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #3621 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in LAB as recently as Q3 2025.

Clearstead Advisors first reported a position in LAB in Q2 2025 and has held it in 3 quarters since. The position peaked at $280 in Q3 2025. 40 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Clearstead Advisors held 11 shares of Standard BioTools worth $10 as of Q2 2026.
  • Standard BioTools was a new Clearstead Advisors position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3621 holding.
  • Clearstead Advisors first reported a position in Standard BioTools in Q2 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Standard BioTools position peaked at $280 in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.